vs
Side-by-side financial comparison of Guardant Health, Inc. (GH) and Wendy's Co (WEN). Click either name above to swap in a different company.
Wendy's Co is the larger business by last-quarter revenue ($523.5M vs $281.3M, roughly 1.9× Guardant Health, Inc.). Wendy's Co runs the higher net margin — 7.5% vs -45.7%, a 53.2% gap on every dollar of revenue. On growth, Guardant Health, Inc. posted the faster year-over-year revenue change (39.4% vs -3.2%). Wendy's Co produced more free cash flow last quarter ($68.0M vs $-54.2M). Over the past eight quarters, Guardant Health, Inc.'s revenue compounded faster (29.2% CAGR vs -4.2%).
Guardant Health, Inc. is an American biotechnology company based in Palo Alto, California. Co-founders Helmy Eltoukhy and AmirAli Talasaz serve as co-chief executive officers.
The Wendy's Company is an American fast food corporation and the holding company for Wendy's and First Kitchen. Originally founded as the Deisel-Wemmer Company, it is headquartered in Dublin, Ohio. The company's principal subsidiary, Wendy's International, is the franchisor of Wendy's restaurants.
GH vs WEN — Head-to-Head
Income Statement — Q4 FY2025 vs Q1 FY2027
| Metric | | |
|---|---|---|
| Revenue | $281.3M | $523.5M |
| Net Profit | $-128.5M | $39.2M |
| Gross Margin | 64.6% | 64.1% |
| Operating Margin | -43.0% | 15.9% |
| Net Margin | -45.7% | 7.5% |
| Revenue YoY | 39.4% | -3.2% |
| Net Profit YoY | -15.8% | 72.7% |
| EPS (diluted) | $-1.01 | $0.19 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | — | $523.5M | ||
| Q4 25 | $281.3M | $543.0M | ||
| Q3 25 | $265.2M | $549.5M | ||
| Q2 25 | $232.1M | $560.9M | ||
| Q1 25 | $203.5M | $523.5M | ||
| Q4 24 | $201.8M | $574.3M | ||
| Q3 24 | $191.5M | $566.7M | ||
| Q2 24 | $177.2M | $570.7M |
| Q1 26 | — | $39.2M | ||
| Q4 25 | $-128.5M | $26.5M | ||
| Q3 25 | $-92.7M | $44.3M | ||
| Q2 25 | $-99.9M | $55.1M | ||
| Q1 25 | $-95.2M | $39.2M | ||
| Q4 24 | $-111.0M | $47.5M | ||
| Q3 24 | $-107.8M | $50.2M | ||
| Q2 24 | $-102.6M | $54.6M |
| Q1 26 | — | 64.1% | ||
| Q4 25 | 64.6% | 62.7% | ||
| Q3 25 | 64.7% | 62.8% | ||
| Q2 25 | 65.0% | 65.0% | ||
| Q1 25 | 63.3% | 64.1% | ||
| Q4 24 | 61.6% | 65.9% | ||
| Q3 24 | 61.1% | 65.5% | ||
| Q2 24 | 59.1% | 65.0% |
| Q1 26 | — | 15.9% | ||
| Q4 25 | -43.0% | 11.8% | ||
| Q3 25 | -37.3% | 16.8% | ||
| Q2 25 | -45.9% | 18.6% | ||
| Q1 25 | -54.6% | 15.9% | ||
| Q4 24 | -62.4% | 16.7% | ||
| Q3 24 | -61.3% | 16.7% | ||
| Q2 24 | -56.8% | 17.4% |
| Q1 26 | — | 7.5% | ||
| Q4 25 | -45.7% | 4.9% | ||
| Q3 25 | -35.0% | 8.1% | ||
| Q2 25 | -43.0% | 9.8% | ||
| Q1 25 | -46.8% | 7.5% | ||
| Q4 24 | -55.0% | 8.3% | ||
| Q3 24 | -56.3% | 8.9% | ||
| Q2 24 | -57.9% | 9.6% |
| Q1 26 | — | $0.19 | ||
| Q4 25 | $-1.01 | $0.14 | ||
| Q3 25 | $-0.74 | $0.23 | ||
| Q2 25 | $-0.80 | $0.29 | ||
| Q1 25 | $-0.77 | $0.19 | ||
| Q4 24 | $-0.90 | $0.23 | ||
| Q3 24 | $-0.88 | $0.25 | ||
| Q2 24 | $-0.84 | $0.27 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $378.2M | $300.8M |
| Total DebtLower is stronger | $1.5B | $2.8B |
| Stockholders' EquityBook value | $-99.3M | $117.4M |
| Total Assets | $2.0B | $5.0B |
| Debt / EquityLower = less leverage | — | 23.51× |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | $300.8M | ||
| Q4 25 | $378.2M | $300.8M | ||
| Q3 25 | $580.0M | $291.4M | ||
| Q2 25 | $629.1M | $281.2M | ||
| Q1 25 | $698.6M | $335.3M | ||
| Q4 24 | $525.5M | $450.5M | ||
| Q3 24 | $585.0M | $482.2M | ||
| Q2 24 | $933.7M | $465.5M |
| Q1 26 | — | $2.8B | ||
| Q4 25 | $1.5B | $2.8B | ||
| Q3 25 | $1.1B | $2.7B | ||
| Q2 25 | $1.1B | $2.7B | ||
| Q1 25 | $1.1B | $2.7B | ||
| Q4 24 | $1.1B | $2.7B | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
| Q1 26 | — | $117.4M | ||
| Q4 25 | $-99.3M | $117.4M | ||
| Q3 25 | $-354.5M | $109.2M | ||
| Q2 25 | $-305.5M | $112.9M | ||
| Q1 25 | $-250.8M | $130.2M | ||
| Q4 24 | $-139.6M | $259.4M | ||
| Q3 24 | $-60.1M | $259.9M | ||
| Q2 24 | $-1.6M | $273.8M |
| Q1 26 | — | $5.0B | ||
| Q4 25 | $2.0B | $5.0B | ||
| Q3 25 | $1.3B | $5.0B | ||
| Q2 25 | $1.3B | $4.9B | ||
| Q1 25 | $1.3B | $4.9B | ||
| Q4 24 | $1.5B | $5.0B | ||
| Q3 24 | $1.5B | $5.1B | ||
| Q2 24 | $1.6B | $5.1B |
| Q1 26 | — | 23.51× | ||
| Q4 25 | — | 23.51× | ||
| Q3 25 | — | 24.95× | ||
| Q2 25 | — | 24.18× | ||
| Q1 25 | — | 21.00× | ||
| Q4 24 | — | 10.57× | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-26.4M | $85.4M |
| Free Cash FlowOCF − Capex | $-54.2M | $68.0M |
| FCF MarginFCF / Revenue | -19.3% | 13.0% |
| Capex IntensityCapex / Revenue | 9.9% | — |
| Cash ConversionOCF / Net Profit | — | 2.18× |
| TTM Free Cash FlowTrailing 4 quarters | $-233.1M | $242.9M |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | $85.4M | ||
| Q4 25 | $-26.4M | $69.3M | ||
| Q3 25 | $-35.4M | $129.3M | ||
| Q2 25 | $-60.3M | $60.6M | ||
| Q1 25 | $-62.7M | $85.4M | ||
| Q4 24 | $-64.5M | $68.6M | ||
| Q3 24 | $-51.1M | $141.2M | ||
| Q2 24 | $-94.0M | $45.5M |
| Q1 26 | — | $68.0M | ||
| Q4 25 | $-54.2M | $31.4M | ||
| Q3 25 | $-45.8M | $104.3M | ||
| Q2 25 | $-65.9M | $39.2M | ||
| Q1 25 | $-67.1M | $67.7M | ||
| Q4 24 | $-83.4M | $26.6M | ||
| Q3 24 | $-55.3M | $123.3M | ||
| Q2 24 | $-99.1M | $28.4M |
| Q1 26 | — | 13.0% | ||
| Q4 25 | -19.3% | 5.8% | ||
| Q3 25 | -17.3% | 19.0% | ||
| Q2 25 | -28.4% | 7.0% | ||
| Q1 25 | -33.0% | 12.9% | ||
| Q4 24 | -41.3% | 4.6% | ||
| Q3 24 | -28.9% | 21.8% | ||
| Q2 24 | -55.9% | 5.0% |
| Q1 26 | — | — | ||
| Q4 25 | 9.9% | 7.0% | ||
| Q3 25 | 3.9% | 4.5% | ||
| Q2 25 | 2.4% | 3.8% | ||
| Q1 25 | 2.2% | 3.4% | ||
| Q4 24 | 9.4% | 7.3% | ||
| Q3 24 | 2.2% | 3.2% | ||
| Q2 24 | 2.9% | 3.0% |
| Q1 26 | — | 2.18× | ||
| Q4 25 | — | 2.62× | ||
| Q3 25 | — | 2.92× | ||
| Q2 25 | — | 1.10× | ||
| Q1 25 | — | 2.18× | ||
| Q4 24 | — | 1.44× | ||
| Q3 24 | — | 2.81× | ||
| Q2 24 | — | 0.83× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
GH
| Oncology | $189.9M | 68% |
| Biopharma Data | $54.0M | 19% |
| Screening | $35.1M | 12% |
| Licensing Other | $2.2M | 1% |
WEN
Segment breakdown not available.
